23J Stock Chart & Stats
€12.20
-€1.10(-9.40%)
At close: 4:00 PM EDT
€12.20
-€1.10(-9.40%)
Day’s Range― - ―
52-Week Range€5.68 - €22.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€88.91M
Enterprise Value€66.85
Total Cash (Recent Filing)€53.46M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Nov 18, 2026EPS Estimate
-1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.89
Shares Outstanding8,967,693
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€37.83Price Target Upside210.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of reported debt reduces near-term solvency pressure and avoids interest obligations while PMN funds clinical development. The improved equity balance provides a stronger capital base than in prior periods, although it does not eliminate the need for future financing.
PMN310 Safety And Biomarker SignalThe interim PMN310 findings support continued clinical development by combining a favorable observed safety profile with biomarker improvements in Alzheimer’s patients. If sustained in the full dataset, this profile could strengthen differentiation against therapies constrained by ARIA risk.
Selective Antibody PlatformA platform focused on pathogenic protein conformations gives PMN a clear scientific strategy across neurodegenerative diseases rather than a single undifferentiated drug concept. Selectivity is intended to improve efficacy and safety, which could support broader development if clinical data validate the approach.
Bears Say
No Operating RevenueThe absence of product revenue means PMN has not yet demonstrated commercial demand or an operating model capable of funding its pipeline. Near-term financial performance therefore depends on clinical progress and access to external capital rather than recurring business cash generation.
Large Recurring LossesThe substantial TTM loss shows that research and clinical development costs currently far exceed any operating income. Continued losses can reduce financial flexibility, increase dependence on capital markets, and make future earnings power highly contingent on successful product development.
Persistent Cash BurnPersistent negative cash flow indicates that PMN is funding operations externally rather than through internally generated resources. If the burn continues, the company may need additional financing to sustain development, creating ongoing funding exposure and potential shareholder dilution.
ProMIS Neurosciences News
23J FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was €5.68 and its highest was €22.00 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is €88.91M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Nov 18, 2026 which is in 49 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Aug 13, 2026. The company reported -€1.095 earnings per share for the quarter, beating the consensus estimate of -€1.18 by €0.085.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.09.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -€1.095 in its last earnings report, beating expectations of -€1.18. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in DE:23J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€37.83 (210.06% Upside)
€37.83 (210.06% Upside)
Blogger Sentiment
Bullish
DE:23J Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth €26.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
496.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
23J Earnings Call
Q2 2026
0:00 / 0:00
23J Stock 12 Month Forecast
Average Price Target
€37.83
▲(210.06% Upside)